Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • Tixagevimab/Cilgavimab Pre-exp...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi

Bibliographic Details
Published in:HemaSphere
Main Authors: Giulia Zamprogna, Anna Maria Frustaci, Giovanna Travi, Chiara Borella, Gianluigi Reda, Marina Motta, Marina Deodato, Elisa Bossi, Veronica Mattiello, Maria Beatrice Ferrari, Giulia Cotilli, Carlo Gambacorti-Passerini, Roberto Cairoli, Massimo Puoti, Alessandra Tedeschi
Format: Article
Language:English
Published: Wiley 2023-05-01
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000880
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/HS9.0000000000000880

Similar Items

  • Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?
    by: Marina Deodato, et al.
    Published: (2022-10-01)
  • Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy
    by: M. V. Zhuravleva, et al.
    Published: (2023-07-01)
  • Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era.
    by: Benjamin Chen, et al.
    Published: (2023-01-01)
  • A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
    by: Takahiro Shimizu, et al.
    Published: (2023-03-01)
  • Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
    by: Benjamin Chen, et al.
    Published: (2023-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs